Research programme: cancer therapeutics - Eli Lilly

Drug Profile

Research programme: cancer therapeutics - Eli Lilly

Alternative Names: DNA checkpoint project - ICOS; Research programme: cell cycle checkpoint/DNA repair inhibitors - ICOS

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator ICOS Corporation
  • Developer Array BioPharma; Eli Lilly
  • Class
  • Mechanism of Action Checkpoint kinase inhibitors; DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Jun 2016 Eli Lilly enters into an agreement with Regen BioPharma to initiate an Open Innovation Drug Discovery Program for the treatment of Cancer
  • 19 Nov 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 22 Apr 2009 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top